Conditions: Breast Neoplasms
Keywords: advanced sunitinib (Sutent) docetaxel Phase 1B
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 22
Healthy volunteers: no

Brief summary:
This study is to evaluate the safety of SU011248 (Sunitinib/Sutent) in combination with docetaxel in patients with metastatic or locally recurrent breast cancer who have not received chemotherapy treatment in the advanced disease setting.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Sunitinib (Sutent) intervention 2: Taxotere
Intervention descriptions: intervention 1: Sunitinib (Sutent) 37.5 mg in schedule 2/1; Sunitinib (Sutent) 37.5 mg in continuous dosing (post discontinuation of axotere) and in accordance with Investigator decision intervention 2: Taxotere 75 mg/m2 iv, once every 3 weeks

Protocol document: